Reference(s)
Click here to return to the Reference Table

Cancer type: Lymphomas


HGF/SF expression

Reference Number: 88
Eagles, G. et al. Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients. Br J Cancer 73, 377-81 (1996).
PubMed link      E-mail link

Reference Number: 172
Capello, D. et al. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia 14, 285-91. (2000).
PubMed link      E-mail link

Reference Number: 173
Gaidano, G. et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol 16, 215-24. (2000).
PubMed link      E-mail link

Reference Number: 174
Hsiao, L. T. et al. High serum hepatocyte growth factor level in patients with non- Hodgkin's lymphoma. Eur J Haematol 70, 282-9. (2003).
PubMed link      E-mail link

Reference Number: 175
Weimar, I. S. et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 89, 990-1000. (1997).
PubMed link      E-mail link

Reference Number: 268
Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur J Maematol 70:282-9 (2003).
PubMed link      E-mail link

Reference Number: 429
Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood107, 760-8 (2006)
PubMed link      E-mail link

Reference Number: 431
Toyama T, Ido A, Sasak H, Maeda K, Yamashita K, Kubuki Y, Suzuki M, Matsuoka H, Tsubouchi H. Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin's lymphoma. Oncol Rep. 13, 439-44 (2005)
PubMed link      E-mail link

Reference Number: 432
Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 128, 210-7 (2005)
PubMed link      E-mail link

Reference Number: 434
Tjin EP, Bende RJ, Derksen PW, van Huijstee AP, Kataoka H, Spaargaren M, Pals ST. Follicular dendritic cells catalyze hepatocyte growth factor (HGF) activation in the germinal center microenvironment by secreting the serine protease HGF activator. Immunol. 175, 2807-13 (2005)
PubMed link      E-mail link

Reference Number: 530
Passam FH, Alexandrakis MG, Moschandrea J, Sfiridaki A, Roussou PA, Siafakas NM. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol. 19, 161-70 (2006)
PubMed link      E-mail link

Reference Number: 630
Etto L, Lacerda E, Baiocchi O, Silva V, Dalboni M, Alves A, Silva M, Vettore A, Colleoni G. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma. 49, 257-64 (2008)
PubMed link      E-mail link

Reference Number: 713
Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F. Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med. 8,141-5 (2008) Epub 2008 Sep 13
PubMed link      E-mail link

Reference Number: 1149
Secchiero P, Corallini F, Zavan B, Tripodo C, Vindigni V, Zauli G. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs. 30, 803-7 (2012)
PubMed link      E-mail link

Met expression

Reference Number: 172
Capello, D. et al. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia 14, 285-91. (2000).
PubMed link      E-mail link

Reference Number: 173
Gaidano, G. et al. Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol 16, 215-24. (2000).
PubMed link      E-mail link

Reference Number: 175
Weimar, I. S. et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 89, 990-1000. (1997).
PubMed link      E-mail link

Reference Number: 176
Jucker, M. et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 18, 7-16. (1994).
PubMed link      E-mail link

Reference Number: 304
Baek CM, Jeon SH, Jang JJ, Lee BS, Lee JH. Transforming variant of Met receptor confers serum independence and anti-apoptotic property and could be involved in the mouse thymic lymphomagenesis. Exp Mil Med 36, 283-91 (2004)
PubMed link      E-mail link

Reference Number: 429
Tjin EP, Groen RW, Vogelzang I, Derksen PW, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood107, 760-8 (2006)
PubMed link      E-mail link

Reference Number: 432
Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 128, 210-7 (2005)
PubMed link      E-mail link

Reference Number: 433
Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, Warner S, Grogan TM, Miller TP. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther. 4, 1867-79 (2005)
PubMed link      E-mail link

Reference Number: 802
Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest. 90, 1346-56 (2010)
PubMed link      E-mail link

Reference Number: 816
Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther. 9, 1244-55 (2010)
PubMed link      E-mail link

Reference Number: 1191
Xu C, Plattel W, van den Berg A, Rüther N, Huang X, Wang M, de Jong D, Vos H, van Imhoff G, Viardot A, Möller P, Poppema S, Diepstra A, Visser L. Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica. 97, 572-8 (2012)
PubMed link      E-mail link

Reference Number: 1338
Huang WT, Chuang SS. High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma. Diagn Pathol. 8, 16 (2013)
PubMed link      E-mail link

Reference Number: 1418
Koh YW1, Hwang HS, Jung SJ, Park C, Yoon DH, Suh C, Huh J. Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP. Cancer Sci. 104, 1245-51 (2013)
PubMed link      E-mail link

Reference Number: 1429
Wha Koh Y1, Park C, Hyun Yoon D, Suh C, Huh J. MET and MST1R as prognostic factors for classical Hodgkin's lymphoma. Mod Pathol. 26, 1172-82 (2013)
PubMed link      E-mail link

Reference Number: 1455
Kikuma K, Yamada K, Nakamura S, Ogami A, Nimura S, Hirahashi M, Yonemasu H, Urabe S, Naito S, Matsuki Y, Sadahira Y, Takeshita M Detailed clinicopathological characteristics and possible lymphomagenesis of type II intestinal enteropathy-associated T-cell lymphoma in Japan. Hum Pathol. 45, 1276-84 (2014)
PubMed link      E-mail link

Reference Number: 1774
Koh YW, Yoon DH, Suh C, Cha HJ, Huh J Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. Int J Exp Pathol. 96, 232-9 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 630
Etto L, Lacerda E, Baiocchi O, Silva V, Dalboni M, Alves A, Silva M, Vettore A, Colleoni G. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. Leuk Lymphoma. 49, 257-64 (2008)
PubMed link      E-mail link

Reference Number: 1338
Huang WT, Chuang SS. High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma. Diagn Pathol. 8, 16 (2013)
PubMed link      E-mail link

Mutation of Met

Reference Number: 339
Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle4, 518-20. Epub 2005 (2005)


PubMed link      E-mail link

In vitro studies

Reference Number: 1
Joseph, A. et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 87, 372-7. (1995).
PubMed link      E-mail link

Reference Number: 172
Capello, D. et al. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia 14, 285-91. (2000).
PubMed link      E-mail link

Reference Number: 175
Weimar, I. S. et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 89, 990-1000. (1997).
PubMed link      E-mail link

Reference Number: 176
Jucker, M. et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 18, 7-16. (1994).
PubMed link      E-mail link

Reference Number: 177
Gonzatti-Haces, M. et al. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A 85, 21-5. (1988).
PubMed link      E-mail link

Reference Number: 178
Pons, E., Uphoff, C. C. & Drexler, H. G. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leuk Res 22, 797-804. (1998).
PubMed link      E-mail link

Reference Number: 431
Toyama T, Ido A, Sasak H, Maeda K, Yamashita K, Kubuki Y, Suzuki M, Matsuoka H, Tsubouchi H. Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin's lymphoma. Oncol Rep. 13, 439-44 (2005)
PubMed link      E-mail link

Reference Number: 816
Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther. 9, 1244-55 (2010)
PubMed link      E-mail link

Reference Number: 1000
Schelter F, Halbgewachs B, Bäumler P, Neu C, Görlach A, Schrötzlmair F, Krüger A. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1a. Clin Exp Metastasis. 28, 91-9 (2011)
PubMed link      E-mail link

Animal models

Reference Number: 179
Weimar, I. S. et al. HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice. Br J Cancer 81, 43-53 (1999).
PubMed link      E-mail link

Reference Number: 339
Graveel CR, London CA, Vande Woude GF. A mouse model of activating Met mutations. Cell Cycle4, 518-20. Epub 2005 (2005)


PubMed link      E-mail link

Reference Number: 682
Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 14, 2220-6 (2008)
PubMed link      E-mail link

Reference Number: 1747
Nakamura M, Takahashi T, Matsui H, Baniwa Y, Takahashi S, Murayama SY, Serizawa H, Suzuki H, Hibi T. Alteration of angiogenesis in Helicobacter heilmannii-induced mucosa-associated lymphoid tissue lymphoma: interaction with c-Met and hepatocyte growth factor. J Gastroenterol Hepatol. 29 Suppl 4:70-6 (2014)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 682
Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 14, 2220-6 (2008)
PubMed link      E-mail link

Reference Number: 710
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6, 3314-22 (2007)
PubMed link      E-mail link

Reference Number: 713
Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F. Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med. 8,141-5 (2008) Epub 2008 Sep 13
PubMed link      E-mail link

Reference Number: 802
Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest. 90, 1346-56 (2010)
PubMed link      E-mail link

Reference Number: 1539
Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res. 201, 197-205 (2014)
PubMed link      E-mail link

Reference Number: 1803
Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D, Parsons C, Reiss K, Zabaleta J, Qin Z. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood. 126, 2821-31 (2015)
PubMed link      E-mail link

Reviews

Reference Number: 887
Mahtouk K, Tjin EP, Spaargaren M, Pals ST. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta. 1806, 208-19 (2010)
PubMed link      E-mail link

Reference Number: 958
Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11, 1477-90 (2010)
PubMed link      E-mail link